ArticleAdvances in therapy2019
Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases.
Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Adherence to biologics in patients with inflammatory bowel disease: a systematic review and meta-analysis.International journal of clinical pharmacy · 2026Pooled it
- Consistent adherence to biologic therapies is critical for improving outcomes in asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large-Scale Multi-Regional Italian Study Through the VALORE Distributed Database.Pharmacoepidemiology and drug safety · 2025Article
- Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.Drugs & aging · 2025Review
- Safety and efficacy of tofacitinib in children with ulcerative colitis complicated with arthropathy: a single-center study.Frontiers in pediatrics · 2025Article
- Estimation of optimal adherence threshold for tumor necrosis factor inhibitors in rheumatoid arthritis.Clinical rheumatology · 2024Article
- Trajectories of adherence to intravenous biological treatment in patients with inflammatory bowel disease: a longitudinal analysis.Frontiers in pharmacology · 2024Article
- Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China.Patient related outcome measures · 2023Article
- Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD.Inflammatory bowel diseases · 2021Article
- Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease.Crohn's & colitis 360 · 2021Article
- Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes.Chest · 2021Article
- Efficacy of JAK inhibitors in Ulcerative Colitis.Journal of Crohn's & colitis · 2020Review
- Comment on: "Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases".Advances in therapy · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients' adherence to and persistence on treatment for inflammatory bowel disease (IBD) can vary, depending on type and distribution of disease and treatment modality. We aim to identify differences in adherence and persistence with treatments with different administration routes (intravenous vs oral) in IBD.
methodsA retrospective cohort analysis of a claims database of adult patients diagnosed with IBD or rheumatoid arthritis (RA) who began treatment with vedolizumab, tofacitinib, or infliximab from January 2015 through December 2015. Adherence evaluated by proportion of days covered (PDC) and cumulative days with gaps at least 20% beyond expected interval (CG20) using multivariable generalized linear equation models. Persistence assessed as time to treatment discontinuation over 12 months of follow-up using Kaplan-Meier estimates and Cox proportional hazards models; proportion of persistent patients determined via multivariable logistic regression. Indirect comparisons across disease states adjusted using infliximab data.
resultsAfter indirect adjustment by disease, mean PDC difference was significantly higher (difference of 4.7%; P = 0.0376) and mean CG20 was lower (difference of 15 days; P = 0.0646) but not statistically significant in vedolizumab/IBD than tofacitinib/RA.
conclusionWe describe a novel adjustment method for interdisease treatment differences using infliximab treatment patterns to bridge differences between IBD and RA. After adjustment, adherence was higher with infusions than oral medications, which may affect outcomes. Indirect comparisons between vedolizumab and tofacitinib are not generalizable and should be confirmed in tofacitinib-treated IBD patients.
fundingTakeda Pharmaceuticals U.S.A., Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.